These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 11807442)

  • 1. Cutaneous manifestations of antiretroviral therapy.
    Ward HA; Russo GG; Shrum J
    J Am Acad Dermatol; 2002 Feb; 46(2):284-93. PubMed ID: 11807442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cutaneous toxicities of antiretroviral therapy for HIV: part I. Lipodystrophy syndrome, nucleoside reverse transcriptase inhibitors, and protease inhibitors.
    Introcaso CE; Hines JM; Kovarik CL
    J Am Acad Dermatol; 2010 Oct; 63(4):549-61; quiz 561-2. PubMed ID: 20846563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Reverse transcriptase inhibitors, protease inhibitors].
    Tachikawa N
    Nihon Rinsho; 2012 Apr; 70(4):579-95. PubMed ID: 22568138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delavirdine: a review of its use in HIV infection.
    Scott LJ; Perry CM
    Drugs; 2000 Dec; 60(6):1411-44. PubMed ID: 11152019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse effects of chronic treatment with the Main subclasses of highly active antiretroviral therapy: a systematic review.
    Silva BF; Peixoto G; da Luz SR; de Moraes S; Peres SB
    HIV Med; 2019 Aug; 20(7):429-438. PubMed ID: 31006976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Role of etravirine in combination antiretroviral therapy].
    Domingo P
    Enferm Infecc Microbiol Clin; 2009 Dec; 27 Suppl 2():46-51. PubMed ID: 20116628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors in the treatment of HIV infections (AIDS).
    De Clercq E
    Adv Pharmacol; 2013; 67():317-58. PubMed ID: 23886005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An open-label, prospective, observational study of the incidence of coronary artery disease in patients with HIV infection receiving highly active antiretroviral therapy.
    Barbaro G; Di Lorenzo G; Cirelli A; Grisorio B; Lucchini A; Hazra C; Barbarini G
    Clin Ther; 2003 Sep; 25(9):2405-18. PubMed ID: 14604740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nucleoside analogue-sparing strategy for the treatment of chronic HIV infection: potential interest and clinical experience.
    Joly V; Yeni P
    Antivir Ther; 2005; 10(1):29-40. PubMed ID: 15751761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human immunodeficiency virus type 1: drug resistance in treated and untreated Brazilian children.
    Simonetti SR; Schatzmayr HG; Simonetti JP
    Mem Inst Oswaldo Cruz; 2003 Sep; 98(6):831-7. PubMed ID: 14595464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hypersensitivity reactions to antiretroviral agents in HIV-infected patients].
    Marcos Bravo MC; Ocampo Hermida A; Moreno Rodilla E
    Med Clin (Barc); 2007 Jan; 128(2):61-9. PubMed ID: 17266904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical pharmacology of nucleoside and nucleotide reverse transcriptase inhibitors].
    Bonora S; Calcagno A; Gonzalez de Requena D; Bargiacchi O; Di Perri G
    Infez Med; 2006 Jun; 14(2):61-70. PubMed ID: 16891850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New antiretroviral drugs, part II: NRTIs, NNRTIs, and beyond.
    Murphy RL
    AIDS Clin Care; 1999 Jun; 11(6):47-9, 51, 53-4. PubMed ID: 11366882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cutaneous toxicities of antiretroviral therapy for HIV: part II. Nonnucleoside reverse transcriptase inhibitors, entry and fusion inhibitors, integrase inhibitors, and immune reconstitution syndrome.
    Introcaso CE; Hines JM; Kovarik CL
    J Am Acad Dermatol; 2010 Oct; 63(4):563-9; quiz 569-70. PubMed ID: 20846564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of adverse events associated with antiretroviral therapy and the relationship to treatment adherence.
    Lenzi L; Wiens A; Pontarolo R
    Int J Clin Pharmacol Ther; 2013 Feb; 51(2):141-6. PubMed ID: 23253950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An introduction to nucleoside and nucleotide analogues.
    Squires KE
    Antivir Ther; 2001; 6 Suppl 3():1-14. PubMed ID: 11678469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiretroviral combination therapy for HIV infection.
    Lewis DA
    Dent Update; 2003 Jun; 30(5):242-7. PubMed ID: 12861761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Non-nucleoside reverse transcriptase inhibitors].
    Joly V; Yeni P
    Ann Med Interne (Paris); 2000 Jun; 151(4):260-7. PubMed ID: 10922953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Warfarin-antiretroviral interactions.
    Liedtke MD; Rathbun RC
    Ann Pharmacother; 2009 Feb; 43(2):322-8. PubMed ID: 19196837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
    Patel N; Abdelsayed S; Veve M; Miller CD
    Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.